Quinazoline derivatives as potential anticancer agents: a patent review (2007 – 2010)

Abstract

From about 1995 to 2006, the anticancer quinazolines panorama has been dominated by the 4-anilinoquinazolines as tyrosine kinase inhibitors. The extensive researches conducted in this period could have caused the progressive reduction in the ability to file novel patents as shown in the 2007 - 2010 period. However, the growing knowledge of cancer-related pathways has recently highlighted some novel potential targets for therapy, with quinazolines receiving increasing attention. This is well demonstrated by the number of different targets of the patents considered in this review. The structural heterogeneity in the patented compounds makes it difficult to derive general pharmacophores and make comparisons among claimed compounds. On the other hand, the identification of multi-target compounds seems a reliable goal. Thus, it is reasonable that quinazoline compounds will be studied and developed for multi-target therapies.

Lewis Acid‐Catalyzed Generation of CC and CN Bonds on π‐Deficient Heterocyclic Substrates

“…[1,2] Cross-coupling reactions able to generate carbon-carbon (C À C) and carbon-nitrogen (C À N) bonds on nitrogen heterocyclic substrates are of great importance in the synthesis of a large variety of bioactive compounds. Some examples include indolylquinolines, which play an important structural role in several biological processes and have been shown to possess antileishmanial and antibacterial activities, [3] derivatives of the quinazoline and acridine nuclei with anticancer, [4,5] antimalarial [6] and a variety of other pharmacological activities, [7] and derivatives of quinoxaline, [8] purine, [9] pyridine [10] and benzimidazole, [11] also with a considerable biomedical interest. Some representative examples are shown in Figure 1.…”

Receptor Chemoprint Derived Pharmacophore Model for Development of CAIX Inhibitors

“…It is because of the presence of quinazoline derivative having piperazine scaffold at one end and azepane ring at the other end. The quinazoline is one of the most widespread chemical scaffolds amongst bioactive compounds and shown a promising results in the development of novel anti-cancer drug molecules [39]. Whereas azepane derivatives possesses anti-cell-proliferation activity [40].…”

The structural optimization of [(2-R-quinazolin-4-ylidene)hydrazono]carboxylic acids and esters – approach for creating a new class of compounds with the anticancer activity

“…Thus, we decided to search a new class of substances with the anticancer activity among 4-substituted quinazolines, namely [(2-Rquinazolin-4-ylidene)hydrazono]carboxylic acids and derived products. Our choice is based on the supposition that combination of hydrazones of alkyl-(aryl-, heteryl-)carboxylic acids with the quinazoline fragment in one molecule, especially taken into account the broad antitumour potential of the latter, [1,2,12,13] is a promising approach of finding new biologically active compounds.…”